ONC BeOne Medicines Ltd.
Nasdaq · SEC CIK 1651308 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $361.20M 49 sales by 12 insiders
- Filings on record
- 271 since 2021-07-01, latest 2026-09-10 16:49
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| OYLER JOHN | CEO, Dir | — | $327.88M |
| Wang Xiaodong | Dir, COB, Scientific Advisory Brd | — | $13.37M |
| Wu Xiaobin | Pres, COO | — | $8.75M |
| Lee Chan Henry | SVP, GC | — | $7.95M |
| Wang Lai | Pres, Gbl Head of R, D | — | $1.17M |
| Sanders Corazon (Corsee) D. | Dir | — | $961.2K |
| Rosenberg Aaron | CFO | — | $524.4K |
| BAKER BROS. ADVISORS LP | Dir | — | $262.0K |
| Ball Titus B. | Principal Accounting Off | — | $127.3K |
| Dugan Margaret | Dir | — | $65.6K |
Transactions 336
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-08-15 | 2025-08-13+ | ONC | Wu Xiaobin | Pres, COO | S - Sale+OE | $304.56 | -89.8K | 33.7K | -73% | -$27.35M |
| DM | 2025-08-15 | 2025-08-13+ | ONC | Wu Xiaobin | Pres, COO | M - OptEx | $160.78 | +89.8K | 22.8K | New | +$14.44M |
| 2025-08-05 | 2025-08-01 | ONC | Rosenberg Aaron | CFO | S - Sale | $290.47 | -1,190 | 0 | -100% | -$345.7K | |
| 2025-07-31 | 2025-07-30 | ONC | Lee Chan Henry | SVP, GC | S - Sale | $304.60 | -920 | 0 | -100% | -$280.2K | |
| MI | 2025-07-31 | 2025-07-29+ | ONC | Wang Lai | Gbl Head of R, D | S - Sale | $302.65 | -4,300 | 259 | -94% | -$1.30M |
| I | 2025-07-22 | 2025-07-18 | ONC | Wang Lai | Gbl Head of R, D | S - Sale | $300.00 | -700 | 0 | -100% | -$210.0K |
| M | 2025-07-11 | 2025-07-09 | ONC | OYLER JOHN | CEO, Dir | S - Sale | $253.38 | -27.8K | 0 | -100% | -$7.04M |
| M | 2025-06-25 | 2025-06-24 | ONC | Wang Xiaodong | Dir, COB, Scientific Advisory Brd | S - Sale | $265.50 | -2,007 | 607 | -77% | -$532.9K |
| 2025-06-25 | 2025-06-23 | ONC | Wu Xiaobin | Pres, COO | S - Sale | $260.00 | -1,363 | 0 | -100% | -$354.4K | |
| M | 2025-06-25 | 2025-06-23 | ONC | OYLER JOHN | CEO, Dir | S - Sale | $261.61 | -3,174 | 0 | -100% | -$830.4K |
| 2025-06-25 | 2025-06-23 | ONC | Wang Lai | Gbl Head of R, D | S - Sale | $260.00 | -1,028 | 0 | -100% | -$267.3K | |
| M | 2025-06-18 | 2025-06-16+ | ONC | Wu Xiaobin | Pres, COO | S - Sale | $261.27 | -2,173 | 730 | -75% | -$567.7K |
| 2025-06-18 | 2025-06-16 | ONC | Lee Chan Henry | SVP, GC | S - Sale | $266.50 | -422 | 0 | -100% | -$112.5K | |
| M | 2025-06-18 | 2025-06-16+ | ONC | OYLER JOHN | CEO, Dir | S - Sale | $263.33 | -5,140 | 1,460 | -78% | -$1.35M |
| M | 2025-06-18 | 2025-06-16+ | ONC | Wang Lai | Gbl Head of R, D | S - Sale | $262.11 | -1,647 | 0 | -100% | -$431.7K |
| 2025-06-12 | 2025-06-11 | ONC | Ball Titus B. | Principal Accounting Off | S - Sale | $258.36 | -134 | 0 | -100% | -$34.6K | |
| 2025-06-12 | 2025-06-10 | ONC | Ball Titus B. | Principal Accounting Off | A - Grant | $0.00 | +29.6K | 74.0K | +67% | $0 | |
| D | 2025-06-12 | 2025-06-10 | ONC | Wang Xiaodong | Dir, COB, Scientific Advisory Brd | M - OptEx | $6.50 | +41.8K | 41.8K | New | +$271.4K |
| DM | 2025-06-12 | 2025-06-10 | ONC | Wang Xiaodong | Dir, COB, Scientific Advisory Brd | S - Sale+OE | $262.82 | -41.8K | 0 | -100% | -$10.98M |
| D | 2025-06-12 | 2025-06-10 | ONC | Wang Xiaodong | Dir, COB, Scientific Advisory Brd | A - Grant | $0.00 | +98.7K | 5.18M | +2% | $0 |
| D | 2025-06-12 | 2025-06-10 | ONC | Rosenberg Aaron | CFO | A - Grant | $0.00 | +63.7K | 230.8K | +38% | $0 |
| D | 2025-06-12 | 2025-06-10 | ONC | OYLER JOHN | CEO, Dir | A - Grant | $0.00 | +185.1K | 8.28M | +2% | $0 |
| D | 2025-06-12 | 2025-06-10 | ONC | Wang Lai | Gbl Head of R, D | A - Grant | $0.00 | +86.4K | 1.06M | +9% | $0 |
| D | 2025-06-12 | 2025-06-10 | ONC | Lee Chan Henry | SVP, GC | A - Grant | $0.00 | +46.9K | 283.9K | +20% | $0 |
| D | 2025-06-12 | 2025-06-10 | ONC | Wu Xiaobin | Pres, COO | A - Grant | $0.00 | +123.4K | 1.27M | +11% | $0 |
| 2025-06-12 | 2025-06-10 | ONC | Yi Qingqing | Dir | J - Other | $0.00 | -29.6K | 27.3K | -52% | $0 | |
| M | 2025-06-10 | 2025-06-06 | ONC | Wang Lai | Gbl Head of R, D | S - Sale | $252.39 | -1,402 | 600 | -70% | -$353.9K |
| M | 2025-06-10 | 2025-06-06 | ONC | Wu Xiaobin | Pres, COO | S - Sale | $253.15 | -1,934 | 1,534 | -56% | -$489.6K |
| M | 2025-06-10 | 2025-06-06 | ONC | Lee Chan Henry | SVP, GC | S - Sale | $256.11 | -700 | 0 | -100% | -$179.3K |
| M | 2025-06-10 | 2025-06-06 | ONC | OYLER JOHN | CEO, Dir | S - Sale | $252.77 | -5,127 | 400 | -93% | -$1.30M |
| D | 2025-05-23 | 2025-05-21 | ONC | Yi Qingqing | Dir | A - Grant | $0.00 | +11.0K | 56.9K | +24% | $0 |
| D | 2025-05-22 | 2025-05-21 | ONC | BRANDICOURT OLIVIER | Dir | A - Grant | $0.00 | +11.0K | 27.3K | +67% | $0 |
| D | 2025-05-22 | 2025-05-21 | ONC | Sharp Shalini | Dir | A - Grant | $0.00 | +11.0K | 19.1K | +135% | $0 |
| D | 2025-05-22 | 2025-05-21 | ONC | HOOPER ANTHONY C | Dir | A - Grant | $0.00 | +11.0K | 64.7K | +20% | $0 |
| D | 2025-05-22 | 2025-05-21 | ONC | Riva Alessandro | Dir | A - Grant | $0.00 | +11.0K | 56.9K | +24% | $0 |
| DMI | 2025-05-22 | 2025-05-21 | ONC | Baker Brothers Life Sciences LP | Dir | A - Grant | $0.00 | +43.9K | 148.1K | +42% | $0 |
| D | 2025-05-22 | 2025-05-21 | ONC | Dugan Margaret | Dir | A - Grant | $0.00 | +11.0K | 56.9K | +24% | $0 |
| D | 2025-05-22 | 2025-05-21 | ONC | Sanders Corazon (Corsee) D. | Dir | A - Grant | $0.00 | +11.0K | 57.2K | +24% | $0 |
| DM | 2025-05-15 | 2025-05-13 | ONC | Wang Xiaodong | Dir, COB, Scientific Advisory Brd | S - Sale+OE | $223.50 | -41.8K | 10.3K | -80% | -$9.33M |
| D | 2025-05-15 | 2025-05-13 | ONC | Wang Xiaodong | Dir, COB, Scientific Advisory Brd | M - OptEx | $6.50 | +41.8K | 41.8K | New | +$271.4K |
| D | 2025-05-13 | 2025-05-09 | ONC | OYLER JOHN | CEO, Dir | F - Tax | $17.85 | -1.99M | 8.16M | -20% | -$35.53M |
| D | 2025-05-13 | 2025-05-09 | ONC | OYLER JOHN | CEO, Dir | M - OptEx | $0.5 | +4.06M | 10.15M | +66% | +$2.03M |
| DM | 2025-04-16 | 2025-04-14 | ONC | Wang Xiaodong | Dir, COB, Scientific Advisory Brd | S - Sale+OE | $242.66 | -41.8K | 7,892 | -84% | -$10.13M |
| D | 2025-04-16 | 2025-04-14 | ONC | Wang Xiaodong | Dir, COB, Scientific Advisory Brd | M - OptEx | $6.50 | +41.8K | 41.8K | New | +$271.4K |
| DM | 2025-04-03 | 2025-04-01 | ONC | Wu Xiaobin | Pres, COO, GM China | S - Sale+OE | $281.39 | -51.9K | 5,083 | -91% | -$14.61M |
| DM | 2025-04-03 | 2025-04-01 | ONC | Wu Xiaobin | Pres, COO, GM China | M - OptEx | $157.14 | +51.9K | 16.5K | New | +$8.16M |
| DM | 2025-03-20 | 2025-03-18 | ONC | Wang Xiaodong | Dir, COB, Scientific Advisory Brd | S - Sale+OE | $261.29 | -41.8K | 29.7K | -58% | -$10.91M |
| D | 2025-03-20 | 2025-03-18 | ONC | Wang Xiaodong | Dir, COB, Scientific Advisory Brd | M - OptEx | $6.50 | +41.8K | 41.8K | New | +$271.4K |
| I | 2025-03-18 | 2025-03-14 | ONC | Wu Xiaobin | Pres, COO, GM China | S - Sale | — | 0 | 0 | New | — |
| 2025-03-13 | 2025-03-11 | ONC | Wang Xiaodong | Dir, COB, Scientific Advisory Brd | G - Gift | $0.00 | -158.7K | 5.08M | -3% | $0 | |
| DM | 2025-03-12 | 2025-03-10 | ONC | OYLER JOHN | CEO, Dir | S - Sale+OE | $242.67 | -41.2K | 39.3K | -51% | -$10.00M |
| DM | 2025-03-12 | 2025-03-10 | ONC | OYLER JOHN | CEO, Dir | M - OptEx | $0.9587 | +539.0K | 41.2K | New | +$516.8K |
| 2025-03-07 | 2025-03-05 | ONC | Lee Chan Henry | SVP, GC | A - Grant | $0.00 | +40.2K | 246.1K | +20% | $0 | |
| D | 2025-03-07 | 2025-03-05 | ONC | OYLER JOHN | CEO, Dir | A - Grant | $0.00 | +201.1K | 4.41M | +5% | $0 |
| DM | 2025-03-07 | 2025-03-06 | ONC | OYLER JOHN | CEO, Dir | M - OptEx | $0.9573 | +526.3K | 40.1K | New | +$503.8K |
| DM | 2025-03-07 | 2025-03-06 | ONC | OYLER JOHN | CEO, Dir | S - Sale+OE | $259.15 | -40.1K | 14.8K | -73% | -$10.39M |
| D | 2025-03-07 | 2025-03-05 | ONC | Wu Xiaobin | Pres, COO, GM China | A - Grant | $0.00 | +103.9K | 1.18M | +10% | $0 |
| DM | 2025-03-07 | 2025-03-05 | ONC | Wu Xiaobin | Pres, COO, GM China | M - OptEx | $126.71 | +51.9K | 51.9K | New | +$6.58M |
| DM | 2025-03-07 | 2025-03-05 | ONC | Wu Xiaobin | Pres, COO, GM China | S - Sale+OE | $261.59 | -51.9K | 0 | -100% | -$13.58M |
| DM | 2025-03-07 | 2025-03-07 | ONC | OYLER JOHN | CEO, Dir | S - Sale+OE | $249.13 | -58.6K | 0 | -100% | -$14.60M |
| DM | 2025-03-07 | 2025-03-07 | ONC | OYLER JOHN | CEO, Dir | M - OptEx | $0.9581 | +767.3K | 58.6K | New | +$735.2K |
| 2025-03-07 | 2025-03-05 | ONC | Wang Lai | Gbl Head of R, D | A - Grant | $0.00 | +69.3K | 990.2K | +8% | $0 | |
| 2025-03-07 | 2025-03-05 | ONC | Rosenberg Aaron | CFO | A - Grant | $0.00 | +48.6K | 167.1K | +41% | $0 | |
| MI | 2025-03-06 | 2025-03-04 | ONC | Wang Xiaodong | Dir, COB, Scientific Advisory Brd | S - Sale | $254.58 | -8,146 | 5,446 | -60% | -$2.07M |
| DM | 2025-03-05 | 2025-03-03 | ONC | OYLER JOHN | CEO, Dir | S - Sale+OE | $244.30 | -101.0K | 95.0K | -52% | -$24.67M |
| DM | 2025-03-05 | 2025-03-03 | ONC | OYLER JOHN | CEO, Dir | M - OptEx | $0.9586 | +1.32M | 4.20M | +46% | +$1.27M |
| I | 2025-03-04 | 2025-02-28 | ONC | Wu Xiaobin | Pres, COO, GM China | S - Sale | — | 0 | 0 | New | — |
| 2025-03-03 | 2025-02-27 | ONC | Lee Chan Henry | SVP, GC | S - Sale | $275.00 | -1,205 | 0 | -100% | -$331.4K | |
| MI | 2025-02-28 | 2025-02-28 | ONC | Baker Bros. Advisors (GP) LLC | Dir | S - Sale | $260.00 | -732.8K | 730.6K | -50% | -$190.54M |
| MI | 2025-02-25 | 2025-02-21 | ONC | Wang Lai | Gbl Head of R, D | S - Sale | $257.23 | -5,000 | 2,619 | -66% | -$1.29M |
| M | 2025-02-25 | 2025-02-21 | ONC | Lee Chan Henry | SVP, GC | S - Sale | $258.04 | -1,202 | 0 | -100% | -$310.2K |
| DM | 2025-02-20 | 2025-02-18+ | ONC | Wu Xiaobin | Pres, COO, GM China | S - Sale+OE | $240.46 | -51.9K | 11.1K | -82% | -$12.49M |
| DM | 2025-02-20 | 2025-02-18+ | ONC | Wu Xiaobin | Pres, COO, GM China | M - OptEx | $169.65 | +51.9K | 30.7K | New | +$8.81M |
| DM | 2025-02-06 | 2025-02-04 | ONC | Wang Xiaodong | Dir, COB, Scientific Advisory Brd | S - Sale+OE | $225.69 | -41.8K | 1,400 | -97% | -$9.42M |
| D | 2025-02-06 | 2025-02-04 | ONC | Wang Xiaodong | Dir, COB, Scientific Advisory Brd | M - OptEx | $6.50 | +41.8K | 41.8K | New | +$271.4K |
| DM | 2025-01-08 | 2025-01-07 | ONC | Wang Xiaodong | Dir, COB, Scientific Advisory Brd | S - Sale+OE | $176.50 | -41.8K | 6,939 | -86% | -$7.37M |
| D | 2025-01-08 | 2025-01-07 | ONC | Wang Xiaodong | Dir, COB, Scientific Advisory Brd | M - OptEx | $6.50 | +41.8K | 41.8K | New | +$271.4K |
| D | 2024-12-17 | 2024-12-14 | ONC | OYLER JOHN | CEO, Dir | M - OptEx | $0.5 | +1.30M | 2.98M | +77% | +$650.0K |
| DM | 2024-12-12 | 2024-12-10 | ONC | Wang Xiaodong | Dir, COB, Scientific Advisory Brd | S - Sale+OE | $186.90 | -41.8K | 2,399 | -95% | -$7.81M |
| D | 2024-12-12 | 2024-12-10 | ONC | Wang Xiaodong | Dir, COB, Scientific Advisory Brd | M - OptEx | $6.50 | +41.8K | 41.8K | New | +$271.4K |
| I | 2024-12-10 | 2024-12-06 | ONC | Wu Xiaobin | Pres, COO, GM China | S - Sale | — | 0 | 0 | New | — |
| MI | 2024-12-10 | 2024-12-09 | ONC | Baker Brothers Life Sciences LP | Dir | S - Sale | $187.27 | -1.04M | 9.66M | -10% | -$194.20M |
| I | 2024-12-04 | 2024-12-02 | ONC | HILLHOUSE INVESTMENT MANAGEMENT, LTD. | 10% | S - Sale | $200.00 | -17.84M | 125.05M | -12% | -$3.57B |
| DMI | 2024-11-29 | 2024-11-26 | ONC | Wang Xiaodong | Dir, COB, Scientific Advisory Brd | S - Sale+OE | $189.97 | -7,883 | 3,608 | -69% | -$1.50M |
| DM | 2024-11-29 | 2024-11-26 | ONC | Wang Xiaodong | Dir, COB, Scientific Advisory Brd | S - Sale+OE | $190.10 | -40.5K | 7,388 | -85% | -$7.69M |
| D | 2024-11-29 | 2024-11-26 | ONC | Wang Xiaodong | Dir, COB, Scientific Advisory Brd | M - OptEx | $6.50 | +38.5K | 40.5K | +1,916% | +$250.0K |
| MI | 2024-10-10 | 2024-10-08 | ONC | OYLER JOHN | CEO, Dir | S - Sale | $232.22 | -10.0K | 0 | -100% | -$2.32M |
| M | 2024-10-10 | 2024-10-08 | ONC | OYLER JOHN | CEO, Dir | S - Sale | $232.22 | -6,175 | 4,610 | -57% | -$1.43M |
| 2024-10-02 | 2024-09-30 | ONC | Lee Chan Henry | SVP, GC | S - Sale | $237.10 | -1,202 | 0 | -100% | -$285.0K | |
| D | 2024-10-02 | 2024-09-30 | ONC | Sharp Shalini | Dir | A - Grant | $0.00 | +8,151 | 8,151 | New | $0 |
| I | 2024-10-01 | 2024-09-27 | ONC | Wang Lai | Gbl Head of R, D | S - Sale | $220.35 | -5,000 | 0 | -100% | -$1.10M |
| M | 2024-09-19 | 2024-09-17+ | ONC | Wu Xiaobin | Pres, COO, GM China | S - Sale | $200.13 | -5,000 | 4,500 | -53% | -$1.00M |
| 2024-09-05 | 2024-09-03 | ONC | Ball Titus B. | Principal Accounting Off | S - Sale | $189.94 | -137 | 0 | -100% | -$26.0K | |
| M | 2024-09-05 | 2024-09-03 | ONC | Wu Xiaobin | Pres, COO, GM China | S - Sale | $189.65 | -5,556 | 274 | -95% | -$1.05M |
| 2024-08-14 | 2024-08-12 | ONC | Wang Xiaodong | Dir, COB, Scientific Advisory Brd | G - Gift | $0.00 | -301.5K | 5.27M | -5% | $0 | |
| D | 2024-08-13 | 2024-08-09 | ONC | Rosenberg Aaron | CFO | A - Grant | $0.00 | +118.5K | 118.5K | New | $0 |
| 2024-08-01 | 2024-07-30 | ONC | Lee Chan Henry | SVP, GC | S - Sale | $160.57 | -834 | 0 | -100% | -$133.9K | |
| 2024-07-03 | 2024-07-01 | ONC | Wang Julia Aijun | CFO | S - Sale | $143.90 | -472 | 0 | -100% | -$67.9K | |
| M | 2024-06-26 | 2024-06-24 | ONC | Wang Lai | Gbl Head of R, D | S - Sale | $159.80 | -1,064 | 0 | -100% | -$170.0K |
| M | 2024-06-26 | 2024-06-24 | ONC | Wu Xiaobin | Pres, COO, GM China | S - Sale | $159.79 | -1,459 | 0 | -100% | -$233.1K |
Purchase Sale Sale after option exercise All abbreviations